Tocilizumab for refractory cerebral arteritis in a patient with systemic lupus erythematosus: A case report

Clicks: 11
ID: 330688
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #55 of 59 articles by views in Modern Rheumatology Case Reports

Most read Least read

Bar heights use a square-root scale.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Cerebral arteritis is a rare (<1%) but life-threatening manifestation of systemic lupus erythematosus (SLE). The optimal treatment of cerebral arteritis in refractory cases remains unclear; conventional immunosuppressive therapy results in improvement in arterial stenosis in only 29% of reported cases. We report a 51-year-old woman with a 20-year history of SLE and rheumatoid arthritis who developed aphasia and right hemiparesis due to haemodynamic cerebral infarction caused by cerebral arteritis. Despite treatment with high-dose glucocorticoids, intravenous cyclophosphamide, mycophenolate mofetil, and anifrolumab, the disease remained progressive with persistently elevated C-reactive protein (CRP) levels and worsening arterial stenosis on magnetic resonance angiography (MRA). Cerebrospinal fluid interleukin-6 (IL-6) level was markedly elevated (1590 pg/mL). After switching from anifrolumab to tocilizumab (TCZ), CRP levels normalised, the patient's neurological condition stabilised, and follow-up MRA suggested improvement in arterial stenosis. TCZ might be a viable treatment option for refractory cerebral arteritis in patients with SLE, particularly in cases of elevated cerebrospinal fluid IL-6 levels. To our knowledge, this is the first reported case suggesting the potential efficacy of TCZ in SLE-related cerebral arteritis.
Reference Key
openalex_W7214915048 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Yasuto Minegishi, Takehisa Ogura, Chihiro Imaizumi, Reina Maezawa, Takafumi Uchi, Hideto Kameda
Are you one of these authors? Claim your profile
Journal Modern Rheumatology Case Reports
Year 2026
DOI
10.1093/mrcr/rxag094
URL
https://doi.org/10.1093/mrcr/rxag094
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.